Jing Li, Ph.D.
Department of Oncology
Wayne State University School of Medicine
Director, Pharmacology Core
Karmanos Cancer Institute
4100 John R, HWCRC/Room 523
Mail Code: HW05AO
Detroit, MI 48201
- Clinical pharmacology of anticancer drugs
- Quantitative pharmacology: Physiologically-based pharmacokinetic (PBPK) modeling and simulation; Population pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation
The central theme of my research is to promote rational cancer therapy and drug development by better understanding the clinical pharmacology of anticancer agents, that is, how they behave in patients. My research spans 3 key areas of clinical pharmacology, including:
- Bioanalysis – the development and implementation of analytical techniques for quantitative determination of drugs, metabolites, and proteins in biological samples;
- Pharmacokinetics (PK) – the study of drug absorption, distribution, metabolism, and elimination; and
- Pharmacometabolomics – an emerging field that applies metabolomics to define metabolic signature of drug exposure, thereby providing early insights into mechanism of drug action and biochemical basis for drug response (efficacy or toxicity).
The uniqueness of my work is leveraging in vitro and in vivo drug metabolism and transporter studies, quantitative pharmacology, pharmacometabolomics, and clinical trials to better understand the mechanisms of drug response in patients. Anticancer drugs exhibit large interindividual PK and PD variability that can lead to therapeutic failure or severe toxicity. A better understanding of the mechanisms of PK/PD variability and establishment of PK-PD relationships between the dosing regimen, drug exposure, and response (efficacy or toxicity) are of paramount importance to rational drug development and optimal cancer therapy.
Bao X, Wu J, Kim S, LoRusso P, and Li J. Pharmacometabolomics reveals irinotecan mechanism of action in cancer patients. J Clin Pharmacol 2019;59:20-34.
Li J, Wu J, Bao X, Honea N, Xie Y, Kim S, Sparreboom A, Sanai N. Quantitative and mechanistic understanding of AZD1775 penetration across human blood-brain barrier in glioblastoma patients using an IVIVE-PBPK modeling approach. Clin Cancer Res 2017;23:7454-66.
Li J, Kim S, Shields AF, Douglas KA, McHugh CI, Lawhorn-Crews JM, Wu J, Mangner TJ, LoRusso PM. Integration dynamic positron emission tomography and conventional pharmacokinetic studies to delineate plasma and tumor pharmacokinetics of FAU, a prodrug bioactivated by thymidylate synthase. J Clin Pharmacol. 2016; 56:1433-47.
Wu J, Zhang Y, Wiegand R, Wang J, Bepler G, Li J. Quantitative analysis of intracellular nucleoside triphosphates and other polar metabolites using ion pair reversed-phase liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B 2015;1006:167-78.
Wu J, Shaw J, Dubaisi S, Valeriote F, and Li J. In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radio-protective agent. Drug Metab Dispos 2014;42:2058-67.
Li J, Kim S, Sha X, Wiegand R, Wu J, and LoRusso P. Complex disease-, gene-, and drug-drug interactions: impact of renal function, CYP2D6 status, and OCT2 activity on the pharmacokinetics of veliparib. Clin Cancer Res 2014;20:3931-44.
Complete List of Publications in My Bibliography:
Education and Training:
Ph.D., Pharmaceutical Sciences (2003): National University of Singapore, Singapore
Post-doctoral Fellow, Clinical Pharmacology (2006): Johns Hopkins University, Baltimore, MD
Cancer Biology Courses Taught:
CB7240 Principles of Cancer Therapy
CB7990 Research Technologies in Cancer Research
Pharmacy Program Courses Taught:
PSC7040 Advanced Drug Formulation and Delivery I